The phase III KEYNOTE-204 trial evaluating Keytruda in adult patients with relapsed or refractory classical Hodgkin lymphoma met one of its dual primary endpoints of progression-free survival.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
